Loading…
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $184M | $-50M | $-84M | $-111M | -37.0% | 138.8% | - |
| 2024 | $77M | $-155M | $-175M | $-219M | -62.3% | 32386.9% | - |
| 2023 | $0M | $-175M | $-184M | $-169M | -74.3% | -60.2% | - |
| 2022 | $1M | $-134M | $-142M | $-128M | -177.4% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0.60 | 0.24 | 76.99 | 183.88 |
| Cost Of Revenue | 0 | 0 | 1.26 | 4.75 |
| Gross Profit | 0.60 | 0.24 | 75.74 | 179.14 |
| Operating Expense | 139.15 | 194.18 | 249.47 | 230.69 |
| Operating Income | -138.55 | -193.94 | -173.73 | -51.55 |
| EBITDA | -134.15 | -174.78 | -154.85 | -49.64 |
| EBIT | -135.02 | -175.81 | -156.07 | -50.84 |
| Pretax Income | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income Common Stockholders | -141.90 | -184.13 | -174.57 | -83.50 |
| Total Expenses | 139.15 | 194.18 | 250.73 | 235.43 |
| Interest Expense | 6.88 | 8.31 | 18.50 | 32.66 |
| Interest Income | 2.53 | 18.15 | 19.61 | 18.12 |
| Research And Development | 95.52 | 125.05 | 103.74 | 71.43 |
| Selling General And Administration | 43.63 | 69.14 | 145.73 | 159.26 |
| Normalized EBITDA | -134.15 | -174.78 | -153.14 | -32.61 |
| Normalized Income | -141.90 | -184.13 | -172.87 | -66.49 |
| Basic EPS | -0.37 | -0.32 | -0.27 | -0.13 |
| Diluted EPS | -0.37 | -0.32 | -0.27 | -0.13 |
| Tax Effect Of Unusual Items | 0 | 0 | -0.01 | -0.02 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | -1.71 | -17.03 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | -1.71 | -17.03 |
| Net Income From Continuing Operation Net Minority Interest | -141.90 | -184.13 | -174.57 | -83.50 |
| Reconciled Depreciation | 0.87 | 1.03 | 1.22 | 1.20 |
| Reconciled Cost Of Revenue | 0 | 0 | 1.26 | 4.75 |
| Net Interest Income | -4.35 | 9.84 | 1.10 | -14.54 |
| Net Income From Continuing And Discontinued Operation | -141.90 | -184.13 | -174.57 | -83.50 |
| Total Operating Income As Reported | -138.55 | -193.94 | -173.73 | -68.58 |
| Diluted Average Shares | 380.78 | 570.65 | 646.03 | 666.66 |
| Basic Average Shares | 380.78 | 570.65 | 646.03 | 666.66 |
| Diluted NI Availto Com Stockholders | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income Including Noncontrolling Interests | -141.90 | -184.13 | -174.57 | -83.50 |
| Net Income Continuous Operations | -141.90 | -184.13 | -174.57 | -83.50 |
| Other Income Expense | 1 | -0.02 | -1.94 | -17.41 |
| Other Non Operating Income Expenses | 1 | -0.02 | -0.24 | -0.38 |
| Special Income Charges | 0 | 0 | -1.71 | -17.03 |
| Other Special Charges | 0 | 0 | 1.71 | 0 |
| Restructuring And Mergern Acquisition | 0 | 0 | 0 | 17.03 |
| Net Non Operating Interest Income Expense | -4.35 | 9.84 | 1.10 | -14.54 |
| Interest Expense Non Operating | 6.88 | 8.31 | 18.50 | 32.66 |
| Interest Income Non Operating | 2.53 | 18.15 | 19.61 | 18.12 |
| General And Administrative Expense | 43.63 | 69.14 | 145.73 | 0 |
| Other Gand A | 43.63 | 69.14 | 145.73 | 0 |
| Operating Revenue | 0.60 | 0.24 | 89.92 | 223.37 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Geron Corporationthis co. | GERN | $968M | - | 4.28 | -37.0% | -14.32 |
| Omeros Corporation | OMER | $1.0B | - | -8.61 | 2.8% | -9.24 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.0B | - | 73.41 | 4.0% | 31.98 |
| Aktis Oncology, Inc. | AKTS | $1.0B | - | -0.12 | 43.6% | -15.93 |
| Collegium Pharmaceutical, Inc. | COLL | $1.0B | 16.75 |
| 3.49 |
| 20.8% |
| 4.08 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $1.0B | 9.72 | 1.21 | 12.4% | 6.78 |
| Annexon, Inc. | ANNX | $957M | - | 4.16 | -97.7% | -3.42 |
| Phathom Pharmaceuticals, Inc. | PHAT | $936M | - | -1.92 | 50.5% | -8.71 |
| Lumexa Imaging Holdings, Inc. | LMRI | $901M | - | 1.54 | -8.0% | 19.62 |
| Peer Median | - | 13.24 | 1.37 | 8.2% | 0.33 | |